A Class in Session: Understanding Current and Future Therapeutic Advances Across B-Cell Lymphomas

In this comprehensive online program experts discuss how to select optimal therapies for patients with B-cell lymphomas. Get up to date with expert commentaries an on-demand webcast and slides from a dynamic CCO symposium at ASH 2021 downloadable resources on 10 key agent classes and an audio podcast.

Share

Program Content

No activities added yet

Activities

Sequencing FL Therapy
How I Sequence Therapy for Patients With Follicular Lymphoma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 01, 2021

Expires: October 31, 2022

Sequencing BTKi in MZL
Sequencing BTK Inhibitors in Treatment of Marginal Zone Lymphomas
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 02, 2021

Expires: November 01, 2022

Treating MCL
How I Treat Patients With Mantle Cell Lymphoma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 12, 2021

Expires: November 11, 2022

Treating DLBCL
How I Sequence Treatment for Patients With Diffuse Large B-Cell Lymphoma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: December 01, 2021

Expires: November 30, 2022

Treating EBV+ PTLD
How I Treat Patients With EBV-Associated Posttransplant Lymphoproliferative Disease
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2021

Expires: December 05, 2022

Activities

Advances in FL
New Advances in Follicular Lymphoma
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2021

Expires: December 14, 2022

Advances in DLBCL
New Advances in Diffuse Large B-Cell Lymphoma
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

Advances in MZL and MCL
What’s New in Marginal Zone Lymphoma and Mantle Cell Lymphoma?
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

EBV-Associated PTLD
Novel Approaches to the Treatment of EBV-Associated Post-Transplant Lymphoproliferative Disorders
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

<i>EP</i>: Advances in B-Cell Lymphomas
ExpressPoints: Understanding Current and Future Therapeutic Advances Across B-Cell Lymphomas
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: January 04, 2022

Activities

CAR T-cells for B-Cell Lymphomas
CAR T-cell Therapy in B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2021

Expires: December 09, 2022

BCL-2 in B-Cell Lymphomas
BCL-2 Targeted Therapy in B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2021

Expires: December 09, 2022

PI3Ki in B-Cell Lymphomas
PI3K Inhibitors in B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2021

Expires: December 12, 2022

Epigenetic Therapies in B-Cell Lymphomas
Epigenetic Therapies in B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2021

Expires: December 12, 2022

Ab-Based Tx in B-cell Lymphomas
Antibody-Based Therapies for B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

Bispecific Abs in B-Cell Lymphomas
Bispecific Antibodies in B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: December 27, 2021

Expires: December 26, 2022

IMiDs and ICIs for B-Cell Lymphomas
Immunomodulatory Agents and Immune Checkpoint Inhibitors in B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: December 27, 2021

Expires: December 26, 2022

XPO1 Inhibitors for B-Cell Lymphomas
XPO1 and Nuclear Export Inhibitors in B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: December 28, 2021

Expires: December 27, 2022

ADCs for B-Cell Lymphomas
Antibody–Drug Conjugates for B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: December 29, 2021

Expires: December 28, 2022

BTKi for B-Cell Lymphomas
BTK Inhibitors for B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: January 04, 2022

Expires: January 03, 2023

Activities

Advances in B-Cell Lymphomas
Advances in B-Cell Lymphomas: Understanding Current Treatment Approaches
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: February 25, 2022

Expires: February 24, 2023

<i>Podcast Pearls</i>: B Cell Lymphomas
Podcast Pearls: Advances Across B Cell Lymphomas
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: February 25, 2022

Expires: February 24, 2023

Faculty

cover img faculity

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

cover img faculity

Brad S. Kahl, MD

Skoronski Chair of Lymphoma Research
Associate Director for Clinical Research
UW Carbone Cancer Center
University of Wisconsin School of Public Health
Madison, Wisconsin

cover img faculity

John P. Leonard, MD

Chief, Lymphoma/Myeloma Service
Division of Hematology and Oncology
Weill Medical College of Cornell University
New York Presbyterian Hospital
New York Weill Cornell Center
New York, New York

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Atara Biotherapeutics

Bayer Healthcare Pharma

BeiGene, Ltd.

Epizyme

Genentech, a member of the Roche Group

Genmab US

Incyte Corporation

Karyopharm Therapeutics

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc